Clinical trial • Phase III • Other
MIDAZOLAM for Perioperative anxiety
Phase III trial of MIDAZOLAM for Perioperative anxiety.
Overview
- Trial Therapeutic Area
- Other
- Trial Disease
- Perioperative anxiety
- Trial Stage
- Phase III
- Drug Modality
- Small molecule
- Paediatric Trial
- Yes
Key dates
- Initial CTIS Submission Date
- 25-06-2024
- First CTIS Authorization Date
- 10-07-2024
Trial design
Randomised, midazolam oromucosal solution (buccolam 2.5 mg oromucosal solution / midazolam rowa 2.5 mg oromucosal solution) given as premedication (oral; product info indicates dosing units mg/kg and a max total dose of 1 mg/kg), versus handheld-multimedia (tablet/ipad) distraction, versus no anxiolysis (standard care).-controlled Phase III trial in Belgium.
- Randomised
- Yes
- Comparator
- Midazolam oromucosal solution (BUCCOLAM 2.5 mg oromucosal solution / Midazolam Rowa 2.5 mg oromucosal solution) given as premedication (oral; product info indicates dosing units mg/kg and a max total dose of 1 mg/kg), versus handheld-multimedia (Tablet/iPad) distraction, versus no anxiolysis (standard care).
- Target Sample Size
- 150
Eligibility
Recruits 150 paediatric patients.
- Vulnerable Population
- Children aged ≥1 and <8 years are the study population; written informed consent must be provided by the legal parents or caretaker. Assent of the child is not specified in the available documents. Population flagged in system as isVulnerablePopulationSelected: false.
Inclusion criteria
- {"criterion_text":"- Age ≥ 1 year and <8 years old"}
- {"criterion_text":"- ASA 1 or 2"}
- {"criterion_text":"- Elective circumcision, tonsillectomy or adenoidectomy, dental care procedure in day-care"}
- {"criterion_text":"- Written informed consent by the legal parents or caretaker"}
Exclusion criteria
- {"criterion_text":"- Parents of the patient wish not to participate with the study"}
- {"criterion_text":"- Any use of psychoactive medication"}
- {"criterion_text":"- A known photosensitive epilepsy"}
- {"criterion_text":"- A previous operation within 3 months of the time of scheduled operation"}
- {"criterion_text":"- Any other contraindication for the use of the study medication"}
- {"criterion_text":"- Previous history of multiple surgery (>3)"}
- {"criterion_text":"- Parents are not able to give informed consent (language barrier, legally incapable)"}
- {"criterion_text":"- A contraindication for the use of premedication with midazolam"}
- {"criterion_text":"- A known allergy to midazolam"}
- {"criterion_text":"- A contraindication for premedication in general"}
- {"criterion_text":"- A contraindication for the use of a gas-induction/gas-anesthesia"}
- {"criterion_text":"- A contraindication for the use of sevoflurane"}
- {"criterion_text":"- A known mental retardation of the child"}
- {"criterion_text":"- Preoperative behavioral disturbances and psychiatric disorders"}
Endpoints
Primary endpoints
- {"endpoint_text":"- Primary endpoints are the difference in perioperative anxiety between the two groups measured with mYpas-score and parental-scoring with the 5-point anxiety scale.","definition_or_measurement_approach":"Measured using the mYPAS score and parental scoring with a 5-point anxiety scale (parental scoring categories defined elsewhere in the protocol)."}
Secondary endpoints
- {"endpoint_text":"- Stressful inductions (anesthetic satisfaction) Definition of stressful anesthetic inductions will be qualified by scaling and noted by the anesthesiologist, directly post-induction. XML File Identifier: Mmsidp0h9a5a/NwZENxH2Odvq/w= Page 15/25 1. Cooperative Smooth Induction: no crying, no unrest 2. Passive induction: crying, no unrest 3. Anxious induction: crying and unrest 4. Combative induction: total hysteric 2. Parental scoring for anxiety of the patient","definition_or_measurement_approach":"Anesthesiologist-rated scale recorded immediately post-induction with categories: 1 Cooperative Smooth Induction; 2 Passive induction; 3 Anxious induction; 4 Combative induction. Also parental scoring for anxiety."}
- {"endpoint_text":"- Parental scoring for anxiety of the patient will be done by the following the 5-point anxiety scale used: 1. Happy (playing) 2. Happy/little worried (playing cautiously) 3. Worried (no playing, silently) 4. Anxious (crying) 5. Hysterical (crying and screaming) Parental scoring will be done, on the daycare preoperative, on the holding, postoperative on the recovery.","definition_or_measurement_approach":"Parental 5-point anxiety scale applied at preoperative daycare, on the holding area, and postoperative recovery."}
- {"endpoint_text":"- Respiratory postoperative complications Scored directly post-induction and post detubation - Laryngospasm: Four-point scale (17) 1. No Laryngospasm 2. Mild laryngospasm (relieved by jaw thrust and 100% oxygen) 3. Moderate laryngospasm (relieved by 100% oxygen and positive pressure ventilation) 4. Severe laryngospasm (relieved by succinylcholine and intubation)","definition_or_measurement_approach":"Laryngospasm scored on a four-point scale recorded directly post-induction and post-detubation with specified clinical interventions defining severity levels."}
- {"endpoint_text":"- Bronchospasm/wheezing 1. Yes 2. No • In absence of a scale","definition_or_measurement_approach":"Binary recording of bronchospasm/wheezing (Yes/No)."}
- {"endpoint_text":"- Parental Satisfaction on the anxiety-management perioperative: measured on holding, after induction, recovery, postop daycare unit. 1. Extremely satisfied 2. Satisfied 3. Neutral 4. Unsatisfied 5. Extremely Unsatisfactory","definition_or_measurement_approach":"Parental satisfaction measured on a 5-point ordinal scale at multiple perioperative timepoints."}
- {"endpoint_text":"- Postoperative POCIS-Score by leaving the recovery. POCIS is more suitable for young children then the traditional VAS-score (18) See Appendix III of the protocol","definition_or_measurement_approach":"POCIS score assessed at discharge from recovery; protocol appendix referenced for details."}
- {"endpoint_text":"- Preoperative sedation or negative behavior Evaluation of sedation or possible negative behavior preoperative after midazolam is done by the RASS-score. (19) See Appendix III of the protocol","definition_or_measurement_approach":"RASS score used to evaluate sedation or negative behavior preoperatively after midazolam administration; protocol appendix referenced for details."}
Recruitment
- Planned Sample Size
- 150
- Recruitment Window Months
- 95
- Consent Approach
- Written informed consent must be provided by the legal parents or caretaker. Subject information and informed consent forms are available in Dutch (NL) and French (FR) as per available documents. Assent by the child is not specified in the available records.
Geography
- Total Number Of Sites
- 1
- Total Number Of Participants
- 150
Belgium
- Earliest CTIS Part Ii Submission Date
- 10-06-2024
- Latest Decision Or Authorization Date
- 10-07-2024
- Processing Time Days
- 30
- Number Of Sites
- 1
- Number Of Participants
- 150
Sites
- Site Name
- UZ Brussel
- Department Name
- Anesthesiology
- Principal Investigator Name
- Domien Vanhonacker
- Principal Investigator Email
- domien.vanhonacker@uzbrussel.be
- Contact Person Name
- Domien Vanhonacker
- Contact Person Email
- domien.vanhonacker@uzbrussel.be
- Number Of Participants
- 150
Sponsor
Primary sponsor
- Full Name
- UZ Brussel
- Organisation Type
- Hospital/Clinic/Other health care facility
- Country Of Registered Address
- Belgium
Investigational products
- Investigational Product Name
- BUCCOLAM 2.5 mg oromucosal solution
- Active Substance
- MIDAZOLAM
- Modality
- Small molecule
- Routes Of Administration
- ORAL
- Route
- ORAL
- Authorisation Status
- Authorised (marketing authorisation number EU/1/11/709/001)
- Maximum Dose
- 1 mg/kg
- Investigational Product Name
- Midazolam Rowa 2.5 mg oromucosal solution
- Active Substance
- MIDAZOLAM
- Modality
- Small molecule
- Routes Of Administration
- ORAL USE
- Route
- ORAL USE
- Authorisation Status
- Authorised (marketing authorisation number PA0074/099/001)
- Maximum Dose
- 1 mg/kg
Related trials
Other published trials that may interest you.